Background {#Sec1}
==========

Aberrant activation of receptor tyrosine kinases (RTKs) and downstream signaling pathways is ubiquitous in tumor cells, which contributes to the genesis and progression of various types of cancers \[[@CR1]\]. Therefore, RKTs signal pathways have become primary targets for cancer therapy \[[@CR2]\].

Adaptor proteins are the bridging elements that connect the membrane-docking RTKs and downstream signal components in the pathways. They facilitate key signaling transduction events, regulate signal specificity and amplification by providing an essential scaffolding function to recruit signal molecules into signaling networks \[[@CR3]\]. Based on the phosphorylation ability, adaptor proteins are divided into two groups. The first group of adaptor proteins has phosphorylation sites and some feature a membrane docking domain. Group members include GRB2-associated binding protein (GAB), fibroblast growth factor receptor substrate 2 (FRS2), insulin receptor substrate (IRS), Src homology 2-containing protein (SHC), and downstream of the kinase (DOK)-family proteins. The second group comprises GRB2, CRKL, and NCK \[[@CR4]\], on which phosphorylation site is absent. Previous studies have demonstrated that adaptor protein-encoding genes are amplified in various human cancers and considered potential oncogenes, promising prognosticators and therapeutic targets \[[@CR5]--[@CR9]\].

GAB2, CRKL, and FRS2 are three adaptor proteins that exert important roles in signaling transduction of RTKs \[[@CR10]\]. Besides, they have been found to participate in the genesis and progression of various cancers including lung adenocarcinoma, ovarian cancer and breast cancer \[[@CR10]\]. Two earlier studies reported that GAB2 and CRKL were overexpressed in pancreatic ductal adenocarcinoma (PDAC), but they did not investigate the association of GAB2 and CRKL overexpression with the prognosis of PDAC patients \[[@CR11], [@CR12]\]. Also, the clinical significance of FRS2 expression level in PDAC is unrevealed.

The aim of the present study was to explore the expression level of GAB2, FRS2, and CRKL in PDAC and test if there is a relationship between their expressions and the clinicopathological characteristics as well as the prognosis of PDAC.

Methods {#Sec2}
=======

Patients and clinicopathological data {#Sec3}
-------------------------------------

FFPE samples from 77 PDAC patients and fresh samples of three PDAC patients from the pathology department of Peking Union Medical College Hospital between January 2011 and January 2016 were included in the present study according to the following inclusion criteria. 1) PDAC patients without preoperative adjuvant therapy. 2) PDAC patients with complete tumor resection surgery. 3) PDAC patients with complete clinicopathological and follow-up data. 4) Hematoxylin and eosin-stained slides of all samples were reconfirmed by two experienced histopathologists (WLL and WHW). The FFPE specimens were preserved at room temperature, and fresh samples were stored at −80 °C.

Tissue Microarray (TMA) construction {#Sec4}
------------------------------------

H&E slides for each FFPE tissue block were reviewed, and representative tumor and adjacent normal regions were marked on the blocks. Paired cancer and normal cores were punched and transferred to a recipient block to make the TMA block. For each patient, one tumor core and one normal core were taken from the donor block.

Immunohistochemistry staining {#Sec5}
-----------------------------

Immunohistochemistry staining was performed as previously described \[[@CR13]\]. Briefly, 4-μm-thick TMA slides were baked for one hour at 60 °C, deparaffinized, dehydrated and treated in citrate buffer (pH 6.0). The TMA slides were then incubated with 3% hydrogen peroxide at room temperature for one hour, followed by incubation of anti-GAB2 (ab108423, 1:25 dilution, Abcam, Cambridge, UK), CRKL (ab32126; 1:50 dilution; Abcam, Cambridge, UK), and FRS2 (AF4069; 1:25 dilution; R&D, Minneapolis, USA) antibodies at 4 °C overnight. The second day, the slides were incubated with secondary antibodies (Pre-diluted; Zhongshan Golden Bridge, Beijing, China), stained, counterstained, dehydrated, cleared, and mounted. Positive and negative controls were included.

Evaluation of immunohistochemical staining {#Sec6}
------------------------------------------

Staining intensity was assigned to scores 0, 1, 2, 3 representing "no staining," "weak staining," "moderate staining," and "strong staining," respectively. The percentage of positive cancer cells was divided into four bands: "0%", "1--25%", "25--50%", and "\>50%" and was assign to scores of 0 to 3, respectively. By the semi-quantitative immunoreactive score (IRS) system, the final scores of GAB2, CRKL, and FRS2 were calculated according to a general scheme described in \[[@CR14]\]. Briefly, after multiplying the staining intensity score by the staining percentage score, a final score \>2 was considered GAB2 positive; Final score \>0 was considered CRKL positive and final score \>4 was considered FRS2 positive. Co-expression of GAB2/CRKL/FRS2 was defined as the positivity of all three immunomarkers at the same time. The slide was evaluated by two histopathologists, where discrepancies were solved by discussion.

Western blot analysis {#Sec7}
---------------------

Tissue protein lysate was obtained by liquid nitrogen grounding, followed by RIPA buffer digestion and centrifugation. 30 μg tissue lysate per lane was loaded onto 10% sodium dodecyl sulfate (SDS) polyacrylamide gels for electrophoresis, and protein was then transferred to Polyvinylidene difluoride (PVDF) membranes, incubated with primary polyclonal anti-GAB2 (ab108423; 1:1000 dilution; Abcam, Cambridge, UK), CRKL (ab32126; 1:1000 dilution; Abcam, Cambridge, UK), and FRS2 (AF4069; 1:1000 dilution; R&D, Minneapolis, USA) antibodies, respectively. Followed by incubation with the horseradish peroxidase (HRP)---conjugated secondary antibody (1:10000 dilution; Zhongshan Golden Bridge, Beijing, China). The EMD Millipore Immobilon™ Western Chemiluminescent HRP Substrate (Millipore, Darmstadt, Germany) was then applied according to the manufacturer's instructions. Documentation of the chemiluminescence was achieved by exposure on a Carestream X-OMAT BT X-ray film (Carestream, Xiamen, China). The latter was then scanned by a Microtek ScanMaker i700 scanner (Microtek Inc., Shanghai, China).

Statistical analysis {#Sec8}
--------------------

SPSS 17.0 was used to perform the statistical analyses (SPSS Inc., Chicago, IL). The associations between the three proteins and other clinicopathological factor were assessed by *χ* ^2^ test. Kaplan-Meier method and log-rank test were used for survival analysis. Spearman rank correlation analysis was used to analyze the correlation between all the three indexes. The influence of various factors on survival was analyzed individually by univariate survival analysis. Variables with *p* \< 0.05 in the univariate analysis were further analyzed using multivariate analysis. A *p* \< 0.05 was considered statistically significant.

Results {#Sec9}
=======

GAB2, FRS2, and CRKL were frequently expressed in PDAC tissues {#Sec10}
--------------------------------------------------------------

IHC was successful on 75, 76, and 77 cases for GAB2, CRKL, and FRS2, respectively. Failure was attributed to the tissue torn-off from the slides. The demographic characteristics of the 77 patients are shown in Table [1](#Tab1){ref-type="table"}. The positive rates in tumor regions for GAB2, CRKL, and FRS2 were 40.00% (30/75), 53.95% (41/76), and 35.06% (27/77), respectively. Staining patterns of anti-GAB2 and anti-CRKL antibodies were both cytoplasmic and nuclear in the tumor regions, while that of the anti-FRS2 antibody was cytoplasmic and membranous in the tumor regions. GAB2, CRKL, and FRS2 were also expressed in the mesenchymal cells and the infiltrating inflammatory cells (Fig. [1](#Fig1){ref-type="fig"}). Moreover, none of the three proteins were expressed in the normal acinar or ductal epithelial cells. However, they were positive in the pancreatic islets (data not shown). Similarly, Western blot analysis revealed higher levels of GAB2, CRKL, and FRS2 proteins were expressed in PDAC tissues than in the matched adjacent normal tissues (Fig. [2](#Fig2){ref-type="fig"}).Table 1Clinical and pathological characteristics of PDCA patientsParameterNo. of patients (%) Number(%)Sex Female36 (46.75%) Male41 (53.25%)Age at diagnosis  ≤ 6037 (48.05%)  \> 6040 (51.95%)Size (diameter), cm  ≤ 216 (20.78%)  \> 261 (79.22%)Tumor sites Head40 (51.95%) Body/Tail37 (48.05%)Resection margins Negative64 (83.12%) Positive13 (16.88%)Differentiation Well/moderate58 (75.32%) Poor19 (25.68%)Nodal metastasis No30 (38.96%) Yes47 (61.04%)TNM stage I/II65 (84.42%) III/IV12 (15.58%) Fig. 1Expression of GAB2, CRKL and FRS2: GAB−/+ expression (**a**) CRKL−/+ expression (**b**) FRS2−/+ expression (**c**). Magnification × 100 Fig. 2Western blot analyses of GAB2, CRKL and FRS2 expression in PDAC and matched normal tissues. T: PDAC tissue; N: peritumor normal tissue. β-actin was used as a loading control

Correlations among GAB2, FRS2, and CRKL expression {#Sec11}
--------------------------------------------------

Spearman's rank correlation analysis showed that there was a moderately positive correlation between the expression of GAB2 and CRKL (*r* = 0.3742, *P* = 0.001), and a moderately positive correlation between the expression of GAB2 and FRS2 (*r* = 0.5241, *P* \< 0.001). The expression of CRKL was weakly but positively correlated with FRS2 (*r* = 0.2945, *P* = 0.0098) (Fig. [3](#Fig3){ref-type="fig"}).Fig. 3Correlations between GAB2 and CRKL expression, GAB2 and FRS2 expression, and CRKL and FRS2 expression in PDAC: GAB2 expression correlated with CRKL (*r* = 0.3742, *P* = 0.001) (**a**) GAB2 expression correlated with FRS2 (*r* = 0.5241, *P* \< 0.001) (**b**) CRKL expression correlated with FRS2 (*r* = 0.2945, *P* = 0.0098) (**c**)

There was no association between the expression of GAB2, CRKL, FRS2 and other clinicopathologic parameters of PDAC {#Sec12}
------------------------------------------------------------------------------------------------------------------

No significant association was observed between the expression of GAB2, CRKL, FRS2, or the co-expression of GAB/CRKL/FRS2 and the clinicopathological parameters of PDAC patients (Table [2](#Tab2){ref-type="table"}).Table 2Correlation between GAB2/CRKL/FRS2 expression and clinicopathological characteristics of PDCAParameterGAB2 n (%)*P*CRKL n (%)*P*FRS2 n (%)*P*GAB2/CRKL/FRS2 n (%)*P*NegativePositiveNegativePositiveNegativePositiveNegative^a^Positive^b^Sex1.0001.0001.0000.762 Female22(61.1%)14(38.9%)17(47.2%)19(52.8%)23(63.9%)13(36.1%)29(80.6%)7(19.4%) Male23(59.0%)16(41.0%)18(45.0%)22(55.0%)27(65.9%)14(34.1%)35(85.4%)6(14.6%)Age at diagnosis1.0000.6450.8111.000  ≤ 6021(60.0%)14(40.0%)18(50.0%)18(50.0%)25(67.6%)12(32.4%)31(83.6%)6(16.2%)  \> 6024(60.0%)16(40.0%)17(42.5%)23(57.5%)25(62.5%)15(37.5%)33(82.5%)7(17.5%)Size (diameter),0.2550.2600.5570.452  ≤ 2 cm7(46.7%)8(53.3%)5(31.3%)11(68.7%)9(56.3%)7(43.8%)12(75.0%)4(25.0%)  \> 2 cm38(63.3%)22(36.7%)30(50.0%)30(50.0%)41(67.2%)20(32.8%)52(85.2%)9(14.8%)Tumor sites0.2460.6450.1610.367 Head26(66.7%)13(33.3%)17(42.5%)23(57.5%)29(72.5%)11(27.5%)35(87.5%)5(12.5%) Body/Tail19(52.8%)17(47.2%)18(50.0%)18(50.0%)21(56.8%)16(43.2%)29(78.4%)8(21.6%)Resection margins1.0001.0001.0001.000 Negative37(59.7%)25(40.3%)29(46.0%)34(54.0%)41(64.1%)23(35.9%)53(82.8%)11(17.2%) Positive8(61.5%)5(38.5%)6(46.2%)7(53.8%)9(69.2%)4(30.8%)11(84.6%)2(15.4%)Differentiation1.0000.1870.5810.288 Well/moderate34(60.7%)22(39.3%)29(50.9%)28(49.1%)39(67.2%)19(32.8%)50(86.2%)8(13.8%) Poor11(57.9%)8(42.1%)6(31.6%)13(68.4%)11(57.9%)8(42.1%)14(73.7%)5(26.3%)Nodal metastasis0.6400.6420.3370.122 No17(56.7%)13(43.3%)13(41.9%)18(58.1%)18(58.1%)13(41.9%)23(74.2%)8(25.8%) Yes28(62.2%)17(37.8%)22(48.9%)23(51.5%)32(69.6%)14(30.4%)41(89.1%)5(10.9%)TNM stage1.0001.0001.0001.000 I/II38(60.3%)25(39.7%)30(46.2%)35(53.8%)42(64.6%)23(35.4%)54(83.1%)11(16.9%) III/IV7(58.3%)5(41.7%)5(45.5%)6(54.5%)8(66.7%)4(33.3%)10(83.3%)2(16.7%)^a^Negative indicates that one or two of the indexes: GAB2, CRKL, and FRS2 are positive. The three torn-off specimens happened to be from tumors that are negative for one or two of the three proteins and are thus categorized into the GAB2/CRKL/FRS2 negative group despite not knowing the actual expression of one or two of the adaptor proteins^b^Positive indicates all indexes positive of GAB2,CRKL and FRS2

Expression of GAB2, CRKL, FRS2 and co-expression of GAB2 /CRKL/FRS2 were predictors for poor prognosis of PDAC patients {#Sec13}
-----------------------------------------------------------------------------------------------------------------------

The follow-up time of the enrolled patients in our study was between 1 to 5 years. The median DFS was 10.0 months, and the median OS was 16.0 months. In addition to poor tumor differentiation, lymph node metastasis, resection margin, and advanced TNM stage, univariate survival analyses revealed that the expression of GAB2, CRKL, FRS2 and the co-expression of GAB2/CRKL/FRS2 were also indicators for poor clinical outcome. Furthermore, patients co-expressing GAB/CRKL/FRS2 in the tumor had a significantly worse outcome than those with single marker expression (Table [3](#Tab3){ref-type="table"}, Fig. [4](#Fig4){ref-type="fig"}). In the multivariate analysis, poorer tumor differentiation and more advanced TNM stage were independent indicators for unfavorable prognosis regarding both DFS and OS (Table [4](#Tab4){ref-type="table"}), which served as an indicator for the representativeness of the present dataset. Further, multivariate analysis revealed that positive expression of GAB2 increased the hazard ratio of recurrence (PFS), while positive co-expression of GAB2/CRKL/FRS2 increased the hazard ratio of death (OS).Table 3Univariate analyses for DFS and OSVariableDFSOSMedian survival(months)*P*Median survival(months)*P*Sex0.7000.506 Female10.0017.00 Male12.0017.00Age at diagnosis0.7250.212  ≤ 6012.0017.00  \> 6010.0018.00Size (diameter),0.3000.493  ≤ 2 cm14.0018.00  \> 2 cm10.0016.00Tumor sites0.4800.910 Head10.0017.00 Body/Tail12.0017.00Resection margins0.265**0.013** Negative12.0018.00 Positive7.0013.00Differentiation**0.0240.004** Well/moderate12.0019.00 Poor7.0013.00Nodal metastasis0.394**0.076** No12.0019.00 Yes8.0016.00TNM stage**0.001\<0.001** I/II12.0018.00 III/IV5.009.00GAB2 expression**0.0050.031** Negative12.0020.00 Positive7.0015.00CRKL expression**0.0360.020** Negative15.0020.00 Positive7.0015.00FRS2 expression**0.0370.003** Negative12.0021.00 Positive9.0015.00GAB2/CRKL/FRS2 expression**0.0150.001** Negative12.0018.00 Positive4.0010.00Bold values indicate statistical significance Fig. 4Kaplan-Meier curves of DFS and OS with different expression patterns of GAB2, CRKL, and FRS2. DFS according to GAB2 expression pattern (*P* = 0.005) (**a**) CRKL expression pattern (*P* = 0.036) (**b**) FRS2 expression pattern (*P* = 0.037) (**c**) and GAB2/CRKL/FRS2 co-expression pattern (*P* = 0.015) (**d**). OS according to GAB2 expression pattern (*P* = 0.031) (**e**) CRKL expression pattern (*P* = 0.020) (**f**), FRS2 expression pattern (*P* = 0.003) (**g**) and GAB2/CRKL/FRS2 co-expression pattern (*P* = 0.001) (**h**) Table 4Multivariate analyses for DFS and OSParameterHR(95%CI)*P*DFS: Cox regression modelDifferentiation**0.033** Well/moderate Poor2.062(1.059--4.016)TNM stage**0.004** I/II III/IV3.180(1.459--6.928)GAB2 expression**0.018** Negative Positive2.118(1.140--3.936)OS: Cox regression modelDifferentiation**0.043** Well/moderate Poor2.235(1.129--4.422)TNM stage**\<0.001** I/II III/IV7.416(3.052--18.022)GAB2/CRKL/FRS2 coexpression**0.013** Negative Positive2.642(1.226--5.693)Bold values indicate statistical significance

Discussion {#Sec14}
==========

With the development of the inhibition strategies for protein-protein interactions and the emerging disadvantages of traditional targeting therapies, adaptor proteins are becoming promising targets for the therapy of human cancers \[[@CR15]\]. The present study investigated the expression, clinical and prognostic significance of GAB2, CRKL and FRS2 in 77 PDAC patients. Our data demonstrated that GAB2, CRKL, and FRS2 were frequently expressed in PDAC. More importantly, the present study revealed that expression of GAB2, CRKL, FRS2, and the co-expression of GAB2/CRKL/FRS2 predicted poor prognosis for PDAC patients. Finally, expression of GAB2 and co-expression of GAB2/CRKL/FRS2 were independent prognostic factors regarding DFS and OS, respectively.

GAB2 is a key member of adaptor protein family and plays an important role in the tumorigenesis and progression of various human cancers \[[@CR10]\]. A previous study revealed that GAB2 is expressed in PDAC patients by the reverse-phase protein assay (RPPA) \[[@CR11]\]. In the present study, we not only confirmed that GAB2 was expressed in PDAC patients by IHC, but also demonstrated for the first time that GAB2 was associated with a poor outcome of the PDAC patients and that it served as an independent prognostic factor regarding DFS. While several studies indicated that GAB2 was associated with tumor metastasis in breast cancer, colorectal cancer, melanoma, and ovarian cancer \[[@CR16]--[@CR19]\], our study failed to reveal a significant relationship between GAB2 expression and lymph node metastasis in PDAC patients. Our finding indicated that GAB2 might have conferred poorer prognoses for PDAC patients via mechanisms other than facilitating lymph node metastases and further investigation is warranted.

CRKL gene amplification and high levels of protein expression were reported in many human cancers \[[@CR10]\], suggesting that CRKL may act as an oncogene. A previous study demonstrated that high expression of CRKL promoted proliferation and invasion of pancreatic cancer cells, but did not look into the clinicopathological association or prognostic values of this marker \[[@CR12]\]. The present study demonstrated for the first time that high expression of CRKL was associated with a poor prognosis of PDAC, but not with other well-established clinicopathological factors, including lymph node metastasis.

As another member of adaptor proteins, FRS2 was amplified in various human cancers, including ovarian cancer, liposarcoma and glioma \[[@CR6], [@CR20], [@CR21]\]. FRS2 predominantly plays its scaffolding function by regulating key signaling pathways downstream of fibroblast growth factor receptors (FGFRs), which was involved in the pathogenicity of PDAC \[[@CR6], [@CR22]\]. In the present study, we detected the expression of FRS2 in PDAC for the first time. We found that FRS2 was present in 35.06% of PDAC patients. While no significant association was observed between the expression of FRS2 and other clinicopathological factors, it was significantly associated with poor prognosis of PDAC. Our study also revealed that the positive co-expression of GAB2/CRKL/FRS2 was an independent prognostic factor for PDAC.

In the present study, we did not introduce an extra set of training slides that set up the standard for staining intensity as well as the cut-off values for the three adaptor proteins. While allowing for the inclusion of the maximum cases possible in the statistical calculation, the present practice may have brought a certain degree of subjectivity to the interpretation of the IHC results. If GAB2, CRKL, and FRS2 proteins were to be established as new biomarkers for PDAC patients, further validation and standardization processes are compulsory.

Conclusions {#Sec15}
===========

In conclusion, GAB2, CRKL, and FRS2 expression were associated with poor prognosis of PDAC patients. Among them, expression of GAB2 and the co-expression of GAB2/CRKL/FRS2 were independent prognosticators regarding DFS and OS, respectively.

CIs

:   Confidence intervals

CRKL

:   CRK-like protein

DFS

:   Disease-free survival

DOK

:   Downstream of kinase

FFPE

:   Formalin fixed paraffin embedded

FRS2

:   Fibroblast growth factor receptor substrate 2

GAB

:   GRB2-associated binding protein

IRS

:   Immunoreactive score

IRS

:   Insulin receptor substrate

OS

:   Overall survival

PDAC

:   Pancreatic ductal adenocarcinoma

RTKs

:   Receptor tyrosine kinases

SHC

:   Src homology 2-containing protein

We thank Dr. Huanli Duan for her expert assistance with the statistical analyses.

Funding {#FPar1}
=======

This work was supported by the fundings from the National Natural Science Foundation of China (31471366), PUMC Youth Fund (A107000), the Special Foundation for Scientific Research in the Public Interest by the National Health and Family Planning Commission of China (201402001) and Specialized Research Fund for the Doctoral Program of Higher Education of China (81150027).

Availability of data and materials {#FPar2}
==================================

Please contact the author for data requests.

Authors' contributions {#FPar3}
======================

The study was conceived and designed by ZL and LT. The whole experiment was performed by LW and XL. The statistical analysis was conducted by LW, JL, and HW. The manuscript was prepared by LW, JL, and HW. All authors have read and approved the manuscript.

Competing interests {#FPar4}
===================

The authors declare that they have no competing interests.

Consent for publication {#FPar5}
=======================

Not applicable.

Ethics approval and consent to participate {#FPar6}
==========================================

The Ethics Committee of the Peking Union Medical College Hospital (No. S-K118) approved the study. Written informed consent was obtained from all patients at the time of their treatment for the use of material in future research.

Publisher's Note {#FPar7}
================

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
